The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

Scientists have developed a single-dose treatment for breast cancer that eliminates small tumors and significantly shrinks ...

22, 2025 — Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone therapy ...

The typical treatment for estrogen receptor positive (ER+) breast cancer involves surgery and years of hormone therapy that ...

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

A recent study suggests that a simple blood test measuring epigenetic aging could help predict breast cancer risk in older ...

TFPy, developed by researchers at University of Illinois at Urbana-Champaign in US, induces regression of tumours in multiple ...

We all know that a lump in the breast is the classic red flag sign, but that's not what prompted me to get checked out.